Hospital Ernesto Dornelles

Porto Alegre, Rio Grande do Sul 90160-093

2 studies enrolling now · 14 studies all time

What they study most

Atopic Dermatitis, Atrial Fibrillation (AF), Clostridioides Difficile Infection, Covid19, Crohn Disease, Crohn's Disease, Idiopathic Pulmonary Fibrosis, Ulcerative Colitis

Studies at this site

• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation — Recruiting now
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Recruiting now
• Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis — Stopped early
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Completed
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure — Stopped early
• Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed